Trials / Completed
CompletedNCT05155566
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HORMONE RECEPTOR POSITIVE/ HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) Advanced/Metastatic Breast Cancer In Real World Settings
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 847 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Latin America.
Conditions
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2021-03-12
- Completion
- 2021-03-12
- First posted
- 2021-12-13
- Last updated
- 2024-01-26
- Results posted
- 2024-01-26
Locations
2 sites across 2 countries: Argentina, United Kingdom
Source: ClinicalTrials.gov record NCT05155566. Inclusion in this directory is not an endorsement.